1-(3-Methylpyridin-2-yl)piperazine hydrochloride

Catalog No.: 
ACAKXH459
CAS No.: 
2007909-71-7
Molecular Formula: 
C10H16ClN3
Molecular Weight: 
213.71
1-(3-Methylpyridin-2-yl)piperazine hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$108.00InquiryInquiry
1g95%$244.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(3-Methylpyridin-2-yl)piperazine hydrochloride
IUPAC Name1-(3-methylpyridin-2-yl)piperazine hydrochloride
Molecular FormulaC10H16ClN3
Molecular Weight213.71
SMILESCC1=CC=CN=C1N2CCNCC2.[H]Cl
InChI KeySBNAPZWZFDNBED-UHFFFAOYSA-N
Synonym1-(3-Methylpyridin-2-yl)piperazine hydrochloride
CAS No.2007909-71-7
PubChem CID102514748

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACAKXH459 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEUMO414 route compound structure diagram
    ACEUMO41459813-05-7
  2. Plus
  3. ACVODE062 route compound structure diagram
    ACVODE0623430-17-9In Stock
  4. Then
  5. ACAKXH459 route product structure diagram
    ACAKXH4592007909-71-7
Inquiry

2. ACAKXH459 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEUMO414 route compound structure diagram
    ACEUMO41459813-05-7
  2. Plus
  3. ACLHKQ650 route compound structure diagram
    ACLHKQ65018368-76-8In Stock
  4. Then
  5. ACAKXH459 route product structure diagram
    ACAKXH4592007909-71-7
Inquiry

3. ACAKXH459 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEUMO414 route compound structure diagram
    ACEUMO41459813-05-7
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACAKXH459 route product structure diagram
    ACAKXH4592007909-71-7
Inquiry

Comments (0)